A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events

Trial Profile

A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms LEADER
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 27 Jul 2017 According to a Novo Nordisk media release, the European Commission has approved an update to the Victoza (liraglutide) EU label that expands the indication to reflect both improving blood sugar and cardiovascular (CV) events as integral parts of type 2 diabetes treatment.
    • 22 Jun 2017 According to a Novo Nordisk media release, the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has endorsed an update of the European label for Saxenda to included in the trial data for Saxenda label in Europe.
    • 20 Jun 2017 According to a company media release, Novo Nordisk has received positive opinion from the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US FDA for inclusion of the data from this trial in the label for Victoza.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top